These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 23709419)

  • 1. The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma.
    Kim HR; Ahn JR; Lee JG; Bang DH; Ha SJ; Hong YK; Kim SM; Nam KC; Rha SY; Soo RA; Riely GJ; Kim JH; Cho BC
    Yonsei Med J; 2013 Jul; 54(4):865-74. PubMed ID: 23709419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.
    Dogan S; Shen R; Ang DC; Johnson ML; D'Angelo SP; Paik PK; Brzostowski EB; Riely GJ; Kris MG; Zakowski MF; Ladanyi M
    Clin Cancer Res; 2012 Nov; 18(22):6169-77. PubMed ID: 23014527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.
    Paik PK; Johnson ML; D'Angelo SP; Sima CS; Ang D; Dogan S; Miller VA; Ladanyi M; Kris MG; Riely GJ
    Cancer; 2012 Dec; 118(23):5840-7. PubMed ID: 22605530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
    Riely GJ; Kris MG; Rosenbaum D; Marks J; Li A; Chitale DA; Nafa K; Riedel ER; Hsu M; Pao W; Miller VA; Ladanyi M
    Clin Cancer Res; 2008 Sep; 14(18):5731-4. PubMed ID: 18794081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
    Johnson ML; Sima CS; Chaft J; Paik PK; Pao W; Kris MG; Ladanyi M; Riely GJ
    Cancer; 2013 Jan; 119(2):356-62. PubMed ID: 22810899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
    Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers.
    Varghese AM; Sima CS; Chaft JE; Johnson ML; Riely GJ; Ladanyi M; Kris MG
    J Thorac Oncol; 2013 Jan; 8(1):123-5. PubMed ID: 23242442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning.
    Hosgood HD; Pao W; Rothman N; Hu W; Pan YH; Kuchinsky K; Jones KD; Xu J; Vermeulen R; Simko J; Lan Q
    Respir Med; 2013 Nov; 107(11):1755-62. PubMed ID: 24055406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].
    Gao J; Chen JQ; Zhang L; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):652-6. PubMed ID: 23302304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
    Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
    Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
    Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.
    Yamaguchi N; Vanderlaan PA; Folch E; Boucher DH; Canepa HM; Kent MS; Gangadharan SP; Majid A; Kocher ON; Goldstein MA; Huberman MS; Costa DB
    Lung Cancer; 2013 Oct; 82(1):31-7. PubMed ID: 23932486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas.
    Gao B; Sun Y; Zhang J; Ren Y; Fang R; Han X; Shen L; Liu XY; Pao W; Chen H; Ji H
    J Thorac Oncol; 2010 Aug; 5(8):1130-5. PubMed ID: 20559149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma.
    Smits AJ; Kummer JA; Hinrichs JW; Herder GJ; Scheidel-Jacobse KC; Jiwa NM; Ruijter TE; Nooijen PT; Looijen-Salamon MG; Ligtenberg MJ; Thunnissen FB; Heideman DA; de Weger RA; Vink A
    Cell Oncol (Dordr); 2012 Jun; 35(3):189-96. PubMed ID: 22528563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].
    Sun LN; Luan HL; Zang FL; Wang M; Dong N; Guo Y; Sun BC; Zhan ZL
    Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):667-70. PubMed ID: 21122380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
    Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients.
    Bacchi CE; Ciol H; Queiroga EM; Benine LC; Silva LH; Ojopi EB
    Clinics (Sao Paulo); 2012; 67(5):419-24. PubMed ID: 22666783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
    Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.
    Xia N; An J; Jiang QQ; Li M; Tan J; Hu CP
    Exp Lung Res; 2013 Oct; 39(8):328-35. PubMed ID: 23919423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making.
    Campos-Parra AD; Zuloaga C; Manríquez ME; Avilés A; Borbolla-Escoboza J; Cardona A; Meneses A; Arrieta O
    Am J Clin Oncol; 2015 Feb; 38(1):33-40. PubMed ID: 23538866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.